Evidence map›Paper›PMID 34231055›Full record

ArticleVirchows Archiv : an international journal of pathology2021

Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTC1/3-MAML2 genotyping.

André Fehr, Sarah Werenicz, Pietro Trocchi, Markus Falk, Reinhard E Friedrich, Angelika Stammler, Andreas Stang, Florian Oesterling, Laura Khil, Göran Stenman and 3 more

Open access · hybridAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Epidemiology, prognosis, and treatment of head and neck mucoepidermoid carcinoma: a SEER-based analysis of 6228 patients (2004-2020).European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Article
  6. Article
  7. Review
  8. Unilocular cystic mucoepidermoid carcinoma: 6 cases reported and literature review.International journal of clinical and experimental pathology · 2025
    Article
  9. Parotid Gland Tumors: Molecular Diagnostic Approaches.International journal of molecular sciences · 2024
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Case reports in dentistry · 2023
    Article
  15. Development of head and neck pathology in Europe.Virchows Archiv : an international journal of pathology · 2022
    Review
  16. Case reports in dentistry · 2022
    Article
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

André FehrSahlgrenska Center for Cancer Research, Department of Pathology, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden. andre.fehr@gu.se.ORCID http://orcid.org/0000-0002-2657-1392
Sarah WereniczDepartment of Oral and Craniomaxillofacial Surgery, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany.
Pietro TrocchiInstitute of Medical Informatics, Biometry and Epidemiology (IMIBE), University Hospital Essen, Essen, Germany.
Markus FalkInstitute for Hematopathology, Hamburg, Germany.ORCID http://orcid.org/0000-0001-5511-9146
Reinhard E FriedrichDepartment of Oral and Craniomaxillofacial Surgery, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany.ORCID http://orcid.org/0000-0001-7747-9636
Angelika StammlerFaculty of Medicine, Justus-Liebig-University Giessen, Giessen, Germany.
Andreas StangInstitute of Medical Informatics, Biometry and Epidemiology (IMIBE), University Hospital Essen, Essen, Germany.ORCID http://orcid.org/0000-0001-6363-9061
Florian OesterlingCancer Registry North Rhine-Westphalia, Bochum, Germany.ORCID http://orcid.org/0000-0002-5840-8274
Laura KhilCancer Registry North Rhine-Westphalia, Bochum, Germany.
Göran StenmanSahlgrenska Center for Cancer Research, Department of Pathology, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.ORCID http://orcid.org/0000-0003-1017-7363
Werner BöckerGerhard Seifert Reference-Center - Hansepathnet, Hamburg, Germany.
Katharina TiemannInstitute for Hematopathology, Hamburg, Germany.
Thomas LöningGerhard Seifert Reference-Center - Hansepathnet, Hamburg, Germany.ORCID http://orcid.org/0000-0001-6447-8255
Institut für Hämatopathologie Hamburg · DEInstitut für Medizinische Informatik, Biometrie und Epidemiologie · DESahlgrenska University Hospital · SEUniversität Hamburg · DEJustus-Liebig-Universität Gießen · DE

Funding

German Federal Ministry of Education and Science (BMBF) 01ER1704Swedish state under the agreement between the Swedish government and the country councils (ALF) ALFGBG-721711
6 · The paper itself

Abstract

Mucoepidermoid carcinoma (MEC) is the most common carcinoma of the salivary glands. Here, we have used two large patient cohorts with MECs comprising 551 tumors to study clinical, histological, and molecular predictors of survival. One cohort (n = 167), with known CRCT1/3-MAML2 fusion status, was derived from the Hamburg Reference Centre (HRC; graded with the AFIP and Brandwein systems) and the other (n = 384) was derived from the population-based Cancer Registry of North Rhine-Westphalia (LKR-NRW; graded with the AFIP system). The reliability of both the AFIP and Brandwein grading systems was excellent (n = 155). The weighted kappa for inter-rater agreement was 0.81 (95% CI 0.65-0.97) and 0.83 (95% CI 0.71-0.96) for the AFIP and Brandwein systems, respectively. The 5-year relative survival was 79.7% (95% CI 73.2-86.2%). Although the Brandwein system resulted in a higher rate of G3-MECs, survival in G3-tumors (AFIP or Brandwein grading) was markedly worse than in G1/G2-tumors. Survival in > T2 tumors was markedly worse than in those with lower T-stage. Also, fusion-negative MECs had a worse 5-year progression-free survival. The frequency of fusion-positive MECs in the HRC cohort was 78.4%, of which the majority (86.7%) was G1/G2-tumors. In conclusion, the AFIP and Brandwein systems are useful in estimating prognosis and to guide therapy for G3-MECs. However, their significance regarding young age (≤ 30 years) and location-dependent heterogeneity of in particular G2-tumors is more questionable. We conclude that CRTC1/3-MAML2 testing is a useful adjunct to histologic scoring of MECs and for pinpointing tumors with poor prognosis with higher precision, thus avoiding overtreatment.

Indexed as

Gene FusionAdolescentAdultBiomarkers, TumorCarcinoma, MucoepidermoidFemaleGermanyHumansMaleMiddle AgedNeoplasm GradingNeoplasm StagingPredictive Value of TestsProgression-Free SurvivalRegistriesSalivary Gland NeoplasmsBiomarkers, TumorCRTC1 protein, humanCRTC3 protein, humanMAML2 protein, humanTrans-ActivatorsTranscription FactorsCRTC1-MAML2Gene fusionHead and neck neoplasmsMucoepidermoid carcinoma; Neoplasm gradingObserver variation

Identifiers

PMID34231055
PMCPMC8572836
OpenAlexW3180966774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.